
Primary Immunodeficiency Diseases
Description
Primary Immunodeficiency Diseases
Global Primary Immunodeficiency Therapeutics Market to Reach $10.4 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Primary Immunodeficiency Therapeutics estimated at US$6.7 Billion in the year 2020, is projected to reach a revised size of US$10.4 Billion by 2027, growing at a CAGR of 6.4% over the analysis period 2020-2027. Antibody Deficiency, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$6.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cellular Immunodeficiency segment is readjusted to a revised 5.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 5.9% CAGR
The Primary Immunodeficiency Therapeutics market in the U.S. is estimated at US$1.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2027 trailing a CAGR of 5.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.
Innate Immune Disorders Segment to Record 6.2% CAGR
In the global Innate Immune Disorders segment, USA, Canada, Japan, China and Europe will drive the 6.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$669.8 Million in the year 2020 will reach a projected size of US$1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Global Primary Immunodeficiency Therapeutics Market to Reach $10.4 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Primary Immunodeficiency Therapeutics estimated at US$6.7 Billion in the year 2020, is projected to reach a revised size of US$10.4 Billion by 2027, growing at a CAGR of 6.4% over the analysis period 2020-2027. Antibody Deficiency, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$6.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cellular Immunodeficiency segment is readjusted to a revised 5.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 5.9% CAGR
The Primary Immunodeficiency Therapeutics market in the U.S. is estimated at US$1.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2027 trailing a CAGR of 5.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.
Innate Immune Disorders Segment to Record 6.2% CAGR
In the global Innate Immune Disorders segment, USA, Canada, Japan, China and Europe will drive the 6.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$669.8 Million in the year 2020 will reach a projected size of US$1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
Select Competitors (Total 47 Featured) -
- Abbott
- ADMA Biologics
- Astellas
- AstraZeneca
- Baxter International, Inc.
- Bayer
- BDI Pharma
- Bharat Serums and Vaccines
- Bio Products Laboratory Ltd.
- Biocon
- Biotest AG
- Bristol-Myers Squibb
- CSL Behring LLC
- Eli Lilly
- GlaxoSmithKline
- Grifols S.A
- Hualan Biological Engineering
- Kedrion Biopharma
- Kedrion S.p.A.
- LFB S.A.
- Lupin Pharmaceuticals
- Octapharma AG
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
197 Pages
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Primary Immunodeficiency Diseases – Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 2: World Historic Review for Primary Immunodeficiency Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 3: World 15-Year Perspective for Primary Immunodeficiency Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
- TABLE 4: World Recent Past, Current & Future Analysis for Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 5: World Historic Review for Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 6: World 15-Year Perspective for Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 7: World Recent Past, Current & Future Analysis for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 8: World Historic Review for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 9: World 15-Year Perspective for Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 10: World Primary Immunodeficiency Diseases Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
- III. MARKET ANALYSIS
- UNITED STATES
- Primary Immunodeficiency Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
- TABLE 11: USA Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 12: USA Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 13: USA 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- CANADA
- TABLE 14: Canada Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 15: Canada Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 16: Canada 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- JAPAN
- Primary Immunodeficiency Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
- TABLE 17: Japan Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 18: Japan Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 19: Japan 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- CHINA
- Primary Immunodeficiency Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
- TABLE 20: China Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 21: China Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 22: China 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- EUROPE
- Primary Immunodeficiency Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
- TABLE 23: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 24: Europe Historic Review for Primary Immunodeficiency Diseases by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 25: Europe 15-Year Perspective for Primary Immunodeficiency Diseases by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
- TABLE 26: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 27: Europe Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 28: Europe 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- FRANCE
- Primary Immunodeficiency Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
- TABLE 29: France Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 30: France Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 31: France 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- GERMANY
- Primary Immunodeficiency Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
- TABLE 32: Germany Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 33: Germany Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 34: Germany 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- ITALY
- TABLE 35: Italy Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 36: Italy Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 37: Italy 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- UNITED KINGDOM
- Primary Immunodeficiency Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
- TABLE 38: UK Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 39: UK Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 40: UK 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- REST OF EUROPE
- TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 42: Rest of Europe Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 43: Rest of Europe 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- ASIA-PACIFIC
- Primary Immunodeficiency Diseases Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
- TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 45: Asia-Pacific Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 46: Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- REST OF WORLD
- TABLE 47: Rest of World Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Component - Test and Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 48: Rest of World Historic Review for Primary Immunodeficiency Diseases by Component - Test and Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 49: Rest of World 15-Year Perspective for Primary Immunodeficiency Diseases by Component - Percentage Breakdown of Value Sales for Test and Treatment for the Years 2012, 2021 & 2027
- IV. COMPETITION
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.